Floatz logo

N-Butyl Cyanoacrylate

Cholangiocarcinoma

Minia UniversitySmall moleculePhase 3Active
CCC
54/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
73/ 100

Competitive context

91 Active assets in the Cholangiocarcinoma cohort.

Asset / SponsorPhaseRating
Xaliplatin
Jonsson Comprehensive Cancer Center
Phase 3BB
Fluorouracilum
Jonsson Comprehensive Cancer Center
Phase 3BB
Irinotecan
Jonsson Comprehensive Cancer Center
Phase 3B
Docetaxel
Merck Sharp & Dohme LLC
Phase 2B
Etomidate
Cheju Halla General Hospital
Phase 4B

View all 50 →

Same molecule, other indications

N-Butyl Cyanoacrylate is also rated in:

periampullary adenocarcinomaActive
BB
Indicative · Phase 3
64 / 100
View asset →
duodenum cancerActive
B
Indicative · Phase 3
60 / 100
View asset →
bile duct cancerActive
B
Indicative · Phase 3
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →